Zynex (ZYXI) Projected to Post Quarterly Earnings on Wednesday

Zynex (NASDAQ:ZYXI) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Zynex to post earnings of $0.09 per share and revenue of $53.65 million for the quarter.

Zynex Stock Performance

NASDAQ ZYXI opened at $7.66 on Wednesday. Zynex has a 1 year low of $7.15 and a 1 year high of $13.77. The firm has a market capitalization of $243.97 million, a P/E ratio of 51.07 and a beta of 0.54. The firm’s fifty day moving average price is $8.00 and its two-hundred day moving average price is $8.06. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Insider Transactions at Zynex

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total transaction of $78,800.00. Following the sale, the chief financial officer now directly owns 26,299 shares in the company, valued at approximately $207,236.12. The trade was a 27.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 30,000 shares of company stock valued at $236,400. Company insiders own 52.13% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Zynex in a research report on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.